The proportion of patients achieving a prostate-specific antigen nadir less than or equal to 0.2 ng/ml was exactly the same for patients treated with transdermal estradiol patches and those treated ...

Transdermal estradiol patches show similar PSA response to LHRHa when combined with ARPIs in metastatic prostate cancer. The STAMPEDE trial indicates tE2 patches offer a favorable safety profile, ...

Bethesda, MD - In a head-to-head crossover comparison, oral estrogen therapy (ET) was associated with a sustained increase in the inflammatory marker C-reactive protein (CRP) among postmenopausal ...

Based on phase 3 trial findings, investigators conclude that transdermal estradiol should be a standard of care ADT option for patients with nonmetastatic prostate cancer. Transdermal estradiol (tE2) ...

Objective and Design: This multicentre, double-blind, randomised, controlled trial evaluated the efficacy of continuous low-dose transdermal estradiol (E 2-TDS) compared with oral conjugated equine ...

Feb 12 (Reuters) - When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the skin may be just as effective as traditional means of ...

Menopause — the end of a woman’s reproductive years — can bring a range of symptoms, including hot flashes, night sweats, and brain fog. Hormone therapy, to boost the levels of hormones that decrease ...

Share on Pinterest The type of hormone therapy may affect memory performance after menopause, new research suggests. Alfian Widiantono/Getty Images Menopause — the end of a woman’s reproductive years ...